$IMRX News

Cantor Fitzgerald Initiates Coverage On Immuneering with Overweight Rating

Immuneering Appoints Andrew Gengos CFO, Effective July 16

Immuneering Doses First Patient In MAPKeeper 301 Pivotal Phase 3 Clinical Study Of Atebimetinib Plus Modified Gemcitabine/Nab-Paclitaxel To Treat Metastatic Pancreatic Cancer Patients

Immuneering Corporation (IMRX) Discusses Positive Atebimetinib ASCO Data Update in First-Line Pancreatic Cancer Transcript

Immuneering Announces Updated Clinical Data From Ongoing Phase 2a Trial Evaluating Atebimetinib In Combination With mGnP In First-Line Metastatic Pancreatic Ductal Adenocarcinoma

Immuneering Reveals 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy; Tolerability Profile Consistent With Prior Updates; Only Two Categories Of Grade 3 Or Higher Treatment-Related Adverse Events Observed In ≥10% Of Patients, Both Chemotherapy-Related

Immuneering Q1 EPS $(0.21) Beats $(0.26) Estimate

Immuneering Corporation: Updates Inbound At The End Of The Month

We're Hopeful That Immuneering (NASDAQ:IMRX) Will Use Its Cash Wisely

Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting

Immuneering To Present Updated Data From Phase 2a Clinical Trial Evaluating Atebimetinib In Combination With mGnP In First-Line Pancreatic Cancer At 2026 ASCO Annual Meeting

Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond

Immuneering Presents New Genetic Data At 2026 AACR Annual Meeting; Analysis Of Circulating Tumor DNA From Atebimetinib-Treated Patients Shows Acquired MAPK Pathway Alterations Are Rare, Supporting Observed Durable First-Line Activity

Immuneering Presents New Genetic Data At 2026 AACR Annual Meeting; Analysis Of Circulating Tumor DNA From Atebimetinib-Treated Patients Shows Acquired MAPK Pathway Alterations Are Rare, Supporting Observed Durable First-Line Activity

Immuneering CEO Touts 64% 12-Month Survival in Pancreatic Cancer; Phase 3 Launch Nears

Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference

Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival

Immuneering To Present Atebimetinib ctDNA Data Showing Durable Tumor Shrinkage At AACR 2026

Needham Reiterates Buy on Immuneering, Maintains $11 Price Target

Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates